Get the Stockscreener App
3.15
1.61%
0.05
After Hours:
3.25
0.10
+3.17%
Aclarion Inc stock is traded at $3.15, with a volume of 81,111.
It is up +1.61% in the last 24 hours and down -2.48% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
See More
Previous Close:
$3.10
Open:
$3.16
24h Volume:
81,111
Relative Volume:
0.89
Market Cap:
$7.76M
Revenue:
$75,700
Net Income/Loss:
$-7.23M
P/E Ratio:
-0.1831
EPS:
-17.2081
Net Cash Flow:
$-7.37M
1W Performance:
-1.56%
1M Performance:
-2.48%
6M Performance:
-54.31%
1Y Performance:
-58.55%
1-Day Range:
$3.03
$3.19
1-Week Range:
$3.03
$3.35
52-Week Range:
$2.3401
$12.03
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, BTSG, TEM, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
3.15 | 7.63M | 75,700 | -7.23M | -7.37M | -17.21 |
VEEV
Veeva Systems Inc
|
159.42 | 26.00B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
55.50 | 10.68B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
46.95 | 8.70B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
80.46 | 6.90B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
26.45 | 4.85B | 637.78M | 239.40M | 307.21M | 1.1909 |
Aclarion Inc Stock (ACON) Latest News
Insider Move: Aclarion Director Makes Bold New Share Purchase - TipRanks
Aclarion director Scott Breidbart acquires $18,011 in stock By Investing.com - Investing.com India
Aclarion director Scott Breidbart acquires $18,011 in stock - Investing.com
Director at Aclarion (ACON) buys 5,664 Common Stock shares in public trade - Stock Titan
Aclarion director David Neal buys $7,750 in company stock By Investing.com - Investing.com Nigeria
Aclarion director David Neal buys $7,750 in company stock - Investing.com
Aclarion (NASDAQ: ACON) director purchases 2,500 shares in open market trade - Stock Titan
TradingKey - TradingKey
Top Executive Makes Bold Insider Move at Aclarion, Inc. - TipRanks
Aclarion (ACON) CEO makes open-market share purchase - Stock Titan
What Aclarion (ACON) is doing that smart money tracks (Momentum Building) 2026-05-08Oversold Bounce - newser.com
Aclarion (ACON) director adds 1,562 shares in open-market purchase - Stock Titan
ACONW (Aclarion WT) quarterly update shows limited financial disclosure as investors await complete earnings details.High Interest Stocks - newser.com
Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial By Investing.com - Investing.com South Africa
Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial - Investing.com
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment - The Manila Times
Beverly Hills spine practice joins 300-patient back pain trial - Stock Titan
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - Orthopedics This Week
Aclarion Grants Inducement Stock Option to New Western U.S. Commercial Director Amid Growing Demand for Nociscan - citybuzz -
Aclarion Grants Commercial Director Stock Options for 75,000 Shares - geneonline.com
New Western U.S. director gets 17,000-share Aclarion option - Stock Titan
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. - marketscreener.com
Aclarion establishes second trial agreement with Weill Cornell By Investing.com - Investing.com India
Why Aclarion WT (ACONW) might surprise investors this quarter (Smart Money Exits) 2026-05-05Retail Trader Ideas - newser.com
Aclarion establishes second trial agreement with Weill Cornell - Investing.com
Aclarion announces second commercial agreement with Weill Cornell Medicine - marketscreener.com
Weill Cornell adds Aclarion scan to 2-year spine surgery trial - Stock Titan
What Aclarion (ACON) is doing that smarter investors notice (Slips) 2026-05-05Elite Trading Signals - newser.com
ACONW (Aclarion WT) full quarterly earnings data not yet released, investors await key performance and guidance details.Performance Review - newser.com
Aclarion announces $2.5M stock repurchase plan - MSN
Aclarion reports cash runway to ops into late 2027 - BizWest
Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Fueled by Accelerating Clinical Adoption of Nociscan - MEXC Exchange
Aclarion reports 196% jump in Nociscan scan volumes in Q1 - Investing.com UK
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com - Investing.com Australia
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - The Manila Times
Back-pain scan use rose 196% as Aclarion funds operations into 2027 - Stock Titan
Aclarion names Daniel Keefe as commercial director for Western US - Medical Buyer
Is Aclarion (ACON) stock suitable for your portfolio? (-3.26%) 2026-04-29High Attention Stocks - newser.com
Recent Insider BuyingStock ScreenerSnapshot - Finviz
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued ... - Bluefield Daily Telegraph
Aclarion, Inc. Appoints Daniel Keefe as Commercial Director, Western U.S - marketscreener.com
Aclarion (NASDAQ: ACON) expands 2022 equity plan in 2026 shareholder proxy - Stock Titan
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
2.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):